Clinical Trial: A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118527) titled 'A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma' on Aug. 05.

Brief Summary: This study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma

Intervention: DRUG: SHR-A1811 + Ad...